Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43, Implies 59% Upside
Amylyx Pharmaceuticals' average stock price target increased from $42.36 to $43, according to 11 analysts, with a range of $20 to $57. This implies 59% upside from the Oct. 14 closing price. The consensus rating remains 'Buy' among 12 analysts.
How this was made
The 30-second read
Why it matters
The update may influence short-term positioning and options sentiment, but it does not introduce new fundamental information about Amylyx’s pipeline or financials.
Market read
Traders may treat this as incremental bullish sentiment, not a standalone catalyst.
What to watch
The article provides no thesis for the target change, no timing for catalysts, and no discussion of probability-weighted outcomes, which are key for biotech valuation.
Background
This is an aggregator-style note summarizing consensus analyst price targets and ratings for Amylyx Pharmaceuticals.
Ticker impact
The article says Amylyx’s consensus average price target rose from $42.36 to $43, with 11 Buys and 1 Hold.
Likely mild upward bias as traders price in improved Street expectations, but follow-through depends on whether new catalysts (trial, guidance, approvals) emerge.
The only disclosed change is the average target and implied upside; there is no new clinical, regulatory, or financial datapoint in the text.
Market effects
Limited sector read-through because this is a single-name analyst target update without new biotech-specific evidence.
None indicated.
None indicated.
Counterpoint
Price-target hikes often lag or reflect existing expectations; without new trial or regulatory catalysts, the stock may not re-rate materially.
Key entities
- companyAmylyx Pharmaceuticals, Inc.
Subject of the article; consensus average price target raised to $43 and rating remains Buy.
